TIDMAGL
Angle PLC
28 July 2016
For immediate release 28 July 2016
ANGLE plc ("the Company")
USE OF PARSORTIX IN GANNET53 DRUG TRIAL IN OVARIAN CANCER
Over 400 blood samples already processed from 136 ovarian cancer
patients
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company,
is delighted to announce that its Parsortix system has been
formally adopted in the ongoing European wide GANNET53 drug trial,
an ovarian cancer study.
GANNET53 is a large scale FP7 research project funded by the
European Commission investigating use of the drug Ganetespib in
metastatic, p53 mutant, platinum-resistant ovarian cancer. The
project started in October 2013 and runs for 5.5 years with a
budget of EUR6 million. The molecular results in relation to
GANNET53 outcomes will be available at the end of the trial in
2019. More details about the trial are given below.
The Medical University of Vienna, under the leadership of
Professor Robert Zeillinger is responsible for the Companion
Diagnostics part of the trial, which stipulates that "CTC analysis
before and during experimental therapy will be performed and
evaluated for its value to monitor responsiveness to Ganetespib".
The Medical University of Vienna team has worked for many years
with a wide range of CTC systems, both those commercially available
from ANGLE's competitors and new technologies under development
including commercial and academic systems. Due to lack of suitable
cell surface markers, antibody-based CTC systems are ineffective
for ovarian cancer. The best result that has been obtained to date
with other non-antibody based systems is a CTC detection
sensitivity level of 24.5% (i.e. capturing CTCs from only one
quarter of ovarian cancer patients).
Following the Medical University of Vienna's results with
ANGLE's Parsortix system showing "unprecedented sensitivity and
specificity" announced on 27 January 2015, ANGLE were invited by
the consortium to participate in the study. The Medical University
of Vienna commenced testing of GANNET53 blood samples for CTCs
using Parsortix in May 2015. ANGLE's participation is through the
provision of Parsortix loan instruments and cassettes.
The key objectives for ANGLE's participation in the trial are to
(i) to obtain evidence of the capability of the Parsortix system to
harvest cancer cells from patient blood for analysis in large scale
studies to support sales of the system into other drug trials and
(ii) with regard to this specific trial, the possibility that, if
the GANNET53 trial is successful, the Parsortix might subsequently
be utilised as a companion diagnostic to identify patient
responders for Ganetespib.
Formal contractual processes involving the GANNET53 project
partners and the European Commission have been protracted given the
large number of partners involved and have just been completed. The
initial performance of the Parsortix system can now be reported.
The GANNET53 results so far are that:
-- 424 blood samples have been collected from 136 patients. All
these samples have been processed using Parsortix.
-- Molecular analysis of 136 of the Parsortix harvests has so
far been performed in relation to those patients that have finished
therapy. The remaining Parsortix harvests have been stored and
analysis will be undertaken at a later date.
-- In 134 of 136 Parsortix harvests so far analysed, sufficient
RNA could be isolated for further qPCR analysis.
-- The Medical University of Vienna are in the process of
analysing the RNA markers found in the Parsortix harvests to
determine their presence or absence. The study is blinded so
correlation of the results with the patient response or otherwise
to the drug has not yet been evaluated.
Professor Robert Zeillinger, Head of the Molecular Oncology
Group at the Medical University of Vienna, commented:
"For the first time, using the Parsortix system, we can now
reliably access ovarian cancer cells from patient blood samples for
analysis. This opens up completely new approaches to drug
development in ovarian cancer and has the potential for wide
applicability in other ovarian cancer drug trials."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"The integration of our system into drug trials is a key
objective in order to grow research use sales. Today's news follows
Cancer Research UK Manchester Institute's recent incorporation of
Parsortix for routine use in their clinical trials. Performance
demonstrated in the GANNET53 trial and the capability developed by
Medical University of Vienna to analyse the cancer cells has the
potential to open new markets for Parsortix."
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys (Nominated adviser)
Russell Kerr, Oliver Baxendale
(Sales) 020 7397 8900
WG Partners
David Wilson
Claes Spång 020 3705 9330
FTI Consulting
Simon Conway, Mo Noonan,
Stephanie Cuthbert 020 3727 1000
Kimberly Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About GANNET53 http://www.gannet53.eu
GANNET53 is a large scale FP7 research project funded by the
European Commission investigating use of the drug Ganetespib in
metastatic, p53 mutant, platinum-resistant ovarian cancer. The
project started in October 2013 and runs for 5.5 years with a
budget of EUR6 million.
The project is coordinated by Professor Nicole Concin from the
Innsbruck Medical University, Austria. Project partners include
major cancer centres from Austria, Belgium, France and Germany:
-- Medizinische Universität Innsbruck - Austria
-- Katholieke Universiteit Leuven - Belgium
-- Charité - Universitätsmedizin Berlin - Germany
-- Universitätsklinikum Hamburg-Eppendorf - Germany
-- Medizinische Universität Wien - Austria
-- Assistance Publique - Hôpitaux de Paris - France
-- Centre Anticancereux Léon Bérard, Lyon - France
-- AGO Research GmbH - Germany
-- Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie - Germany
-- Association de Recherche dans le Cancers dont Gynécologique -
Groupe des Investigateurs Nationaux dans l'Etude des Cancers
Ovariens (ARCAGY-GINECO), Paris, France
-- Universitätsmedizin Goettingen - Germany
-- OncoLab Diagnostics GmbH - Austria
-- xailabs GmbH - Germany
-- Klinik Essen-Mitte, Evang. Huyssens-Stiftung/ Knappschaft gemeinnützige GmbH - Germany
-- Technische Universität Dresden University Hospital Carl Gustav Carus Dresden - Germany
-- Centre de lutte contre le cancer, Francois Baclesse, Caen CFB France
-- Ernst-Moritz-Arndt-Universität Greifswald - Germany
-- Otto-von-Guericke-Universität Magdeburg - Germany
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, China and
Australia and three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures live cells based on a combination of their size and
compressibility. Parsortix has a CE Mark for Europe and FDA
authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPGUPAMUPQPUM
(END) Dow Jones Newswires
July 28, 2016 02:03 ET (06:03 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Angle (LSE:AGL)
Historical Stock Chart
From Sep 2023 to Sep 2024